RNA-Editing Therapeutics for Selective Correction of Pathogenic Neural Protein Expression

Abstract

RNA-editing therapeutics have emerged as a groundbreaking approach in the selective modification of pathogenic neural protein expression. By harnessing site-directed RNA-editing technologies, clinicians and researchers are now able to correct single nucleotide errors post-transcriptionally, offering targeted treatment for a range of neurogenetic disorders. This review synthesizes recent advances in the field, with an emphasis on scientific mechanisms, clinical applications, and evolving guideline recommendations. We examine the epidemiological impact of neural proteinopathies, delve into the molecular pathophysiology underpinning disease states, and discuss current and future roles for RNA-editing interventions in precision neurology.

Introduction

Neurodegenerative and neurodevelopmental disorders often arise from mutations that alter neural protein expression, leading to profound clinical sequelae. Despite advances in gene therapy, permanent genomic editing remains fraught with safety and ethical concerns. RNA-editing therapeutics, including adenosine deaminases acting on RNA (ADARs) and CRISPR-based platforms, offer a reversible, programmable alternative that can restore physiological protein function. This article provides an in-depth review of RNA-editing strategies for correcting pathogenic neural protein expression, summarizing the clinical implications and translational potential of these therapies.

Epidemiology / Disease Burden

Inherited and sporadic neural proteinopathies such as amyotrophic lateral sclerosis (ALS), Huntington's disease, and certain epileptic encephalopathies collectively affect millions worldwide. The global prevalence of neurodegenerative diseases is projected to rise with an aging population, imposing significant personal, societal, and economic burdens. Many of these conditions are currently incurable, with existing treatments offering only symptomatic relief. The unmet need for disease-modifying therapies underscores the importance of innovative approaches like RNA-editing.

Pathophysiology

Pathogenic mutations in genes encoding neural proteins can result in aberrant protein folding, aggregation, or altered function, disrupting synaptic plasticity and neuronal survival. For example, point mutations in the GRIA2 gene disrupt AMPA receptor editing, leading to increased calcium permeability and excitotoxicity in neurons. RNA-editing enzymes, such as ADARs, catalyze site-specific adenosine-to-inosine (A-to-I) or cytidine-to-uridine (C-to-U) conversions, enabling post-transcriptional correction of deleterious mutations without altering the underlying DNA sequence. This mechanism allows restoration of normal protein function in targeted neuronal populations.

Risk Factors

Risk factors for neural proteinopathies include genetic predisposition, advanced age, environmental neurotoxins, and traumatic brain injury. Polygenic risk and gene-environment interactions may influence disease onset and progression. The presence of specific single nucleotide variants (SNVs) or pathogenic mutations increases susceptibility to protein misfolding disorders and may inform patient selection for RNA-editing interventions.

Clinical Features

Clinical manifestations of neural proteinopathies are highly variable, reflecting the diversity of affected proteins and neuronal circuits. Patients may present with progressive motor dysfunction, cognitive decline, psychiatric symptoms, seizures, or a combination thereof. Disease severity often correlates with the extent of mutant protein expression and neuronal loss. Timely recognition of clinical features is critical for diagnosis, prognostication, and therapeutic planning.

Diagnosis

Diagnosis of pathogenic neural protein expression disorders involves a combination of clinical assessment, neuroimaging, electrophysiological studies, and molecular genetic testing. Next-generation sequencing (NGS) enables identification of causative mutations, while RNA sequencing (RNA-seq) can verify aberrant transcript editing and expression profiles. Biomarker discovery, including quantification of misfolded proteins in cerebrospinal fluid, further aids in diagnosis and monitoring.

Treatment & Management

Current management strategies for neural proteinopathies are largely supportive, comprising pharmacological agents, physical therapy, and multidisciplinary care. Disease-modifying therapies remain limited. RNA-editing therapeutics represent an emerging modality designed to correct mutant transcripts, potentially halting or reversing pathogenic protein production. Delivery methods under investigation include viral vectors, lipid nanoparticles, and engineered RNA-guided complexes, each offering distinct advantages for targeting neuronal tissues.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the development of programmable RNA-editing tools. Engineered ADARs, guide RNAs, and CRISPR-Cas13 systems have demonstrated preclinical efficacy in mouse models of ALS, Rett syndrome, and Dravet syndrome by selectively correcting pathogenic transcripts. Notably, in vivo studies have reported durable editing with minimal off-target effects, supporting clinical translation. Early-phase human trials are underway, evaluating safety, biodistribution, and functional outcomes of RNA-editing therapeutics in neurological diseases.

Guideline Recommendations

While no formal guidelines currently endorse RNA-editing therapy for neural proteinopathies, expert consensus highlights the need for rigorous clinical trial data. Key recommendations include comprehensive genetic screening for candidate selection, longitudinal safety monitoring, and standardized outcome measures. Regulatory pathways are rapidly evolving to accommodate the unique features of RNA-based therapeutics, with emphasis on risk mitigation, informed consent, and transparent reporting of adverse events.

Conclusion

RNA-editing therapeutics represent a transformative advance in the precision treatment of pathogenic neural protein expression. By enabling targeted, reversible correction of disease-causing mutations, these approaches hold promise for addressing unmet needs in neurology. Ongoing research, multidisciplinary collaboration, and robust clinical data will be essential to fully realize the potential of RNA-editing in routine clinical practice, offering hope for patients with previously intractable neurogenetic disorders.